Quest Diagnostics Incorporated DGX
Healthcare · Diagnostics & Research · United States · S&P 500
Based on the available data, Quest Diagnostics Incorporated gets an algorithmic score of 65/100. It trades at 231.97 $, with a bullish technical trend (RSI 42.0) and 24.4% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Attractive free-cash-flow yield (5.3%).
- Low beta (0.17): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 24.65 |
| Forward P/E | 19.24 |
| PEG | 1.53 |
| P/B | 3.39 |
| EV/EBITDA | 14.02 |
| P/S | 2.21 |
| ROE % | 14.60 |
| ROA % | 6.40 |
| Gross margin % | 33.19 |
| Operating margin % | 15.25 |
| Net margin % | 9.19 |
| Revenue growth % (y/y) | 10.20 |
| Earnings growth % (y/y) | 15.00 |
| Revenue CAGR % | 3.74 |
| Earnings CAGR % | 1.60 |
| Debt/Equity % | 81.07 |
| Current ratio | 1.59 |
| FCF yield % | 5.31 |
| Dividend yield % | 1.48 |
| Payout % | 26.11 |
Returns
| 1 month | -4.4 % |
| 3 months | +9.9 % |
| 6 months | +18.6 % |
| YTD | +35.2 % |
| 1 year | +24.9 % |
| 3 years | +99.2 % |
| 5 years | +65.6 % |
Risk
| 1-year volatility | 24.4 % |
| Beta | 0.17 |
| 5-year max drawdown | -28.6 % |
| Sharpe 1A | 0.87 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.